psilocybin micro-dose
Phase 3Small molecule
psilocybin micro-dose is one of 10 small molecule programs targeting Bipolar II Disorder. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Bipolar II Disorder
#DrugCompanyPhaseTrials
1Namenda
AbbVieApproved
Zyprexa
MMODAG GmbH
Approved
Risperdal
WWim Janssens
Approved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Lexapro
AbbViePhase 2
Psilocybin
COMPASS PathwaysPhase 3
psilocybin micro-dose
LLakshmi N Yatham
Phase 3
NMRA-335140
NNeumora Therapeutics, Inc.
Phase 2
GH001
GGH Research Ireland Limited
Phase 2
Psilocybin Therapy
UUniversity of California, San Francisco
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for psilocybin micro-dose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLakshmi N Yatham